Full Press Release Details
JERSEY CITY, N.J.--(BUSINESS WIRE)--Organon reports positive interim Phase 3 results for MIUDELLA®, a hormone-free IUD, through 6 years of use with no new safety signals.
OGN Positive Sentiment
Organon Announces Positive Interim Phase 3 Study Results for MIUDELLA®, a Hormone-Free, Intrauterine Device (IUD), Through 6 Years of Use to Be Presented at the 2026 Society of Family Planning Annual Meeting
Key Takeaway: Organon has announced positive interim results from its Phase 3 study of MIUDELLA®, a hormone-free intrauterine device (IUD). The study indicates that MIUDELLA® is effective through 6 years of use, with no new safety concerns identified. These findings will be presented at the 2026 Society of Family Planning Annual Meeting.
Market Sentiment Analysis
POSITIVE FACTORS
- Positive interim results from Phase 3 study.
- No new safety signals reported.
- MIUDELLA® shows effectiveness over 6 years.
BiopharmaWatch Analysis
From our catalyst data and publicly available data · not financial adviceBest trade, last catalyst
+130%
120-day peak, hindsight
Typical move
3%
average across 6 past catalysts
Lead asset
OG-6219
Phase 2 · Endometriosis
Frequently Asked Questions
What are the results of the MIUDELLA® Phase 3 study?
The Phase 3 study of MIUDELLA® showed positive interim results through 6 years.
Is MIUDELLA® hormone-free?
Yes, MIUDELLA® is a hormone-free intrauterine device.
Will the study results be presented publicly?
Yes, the results will be presented at the 2026 Society of Family Planning Annual Meeting.
Were there any safety concerns with MIUDELLA®?
No new safety signals were reported in the study.